Downregulation of MDR1 gene by cepharanthine hydrochloride is related to the activation of c-Jun/JNK in K562/ADR cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Han, Li ^a   Wang, Yafeng ^b   Guo, Xiaojuan ^a   Zhou, Yubing ^c   Zhang, Jingmin ^b   Wang, Ning ^b   Jiang, Jinhua ^b   Ma, Fang ^b   Wang, Qingduan ^b  

^a NANYANG INSTITUTE OF TECHNOLOGY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CEPHARANTHINE; CEPHARANTHINE HYDROCHLORIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN C JUN; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; BENZYLISOQUINOLINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; K562 CELL LINE; MDR1 GENE; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY; TUMOR CELL LINE;

BENZYLISOQUINOLINES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; P-GLYCOPROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84908330949     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/164391     Document Type: Article

References (29)

1. Pérez-Tomás R., Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Current Medicinal Chemistry 2006 13 16 1859 1876 10.2174/092986706777585077 2-s2.0-33745736603
2. Dong X., Mumper R. J., Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010 5 4 597 615 10.2217/nnm.10.35 2-s2.0-77953368844
3. Zhu A. X., Systemic treatment of hepatocellular carcinoma: dawn of a new era? Annals of Surgical Oncology 2010 17 5 1247 1256 10.1245/s10434-010-0975-6 2-s2.0-77952044952
4. Deferme S., Van Gelder J., Augustijns P., Inhibitory effect of fruit extracts of P-glycoprotein-related efflux carriers: an in-vitro screening. Journal of Pharmacy and Pharmacology 2002 54 9 1213 1219 10.1211/002235702320402053 2-s2.0-0036732050
5. Romiti N., Pellati F., Nieri P., Benvenuti S., Adinolfi B., Chieli E., P-glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line. Planta Medica 2008 74 3 264 266 10.1055/s-2008-1034308 2-s2.0-41349089916
6. Gyémánt N., Engi H., Schelz Z., Szatmári I., Tóth D., Fülöp F., Molnár J., De Witte P. A. M., In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin. The British Journal of Cancer 2010 103 2 178 185 10.1038/sj.bjc.6605716 2-s2.0-77954656220
7. Nemoto K., Yoshida K., Nisimura M., Seki M., The effects of cepharanthin on the recovery of hematopoietic stem cells after X-ray irradiation. Gan To Kagaku Ryoho 1991 18 1 81 84 2-s2.0-0025977983
8. Furusawa S., Wu J., The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sciences 2007 80 12 1073 1079 10.1016/j.lfs.2006.12.001 2-s2.0-33846940700
9. Igari R., Iseki K., Abe S., Syoji M., Sato M., Shimomura K., Hayashida A., Sugiura A., Iwashita Y., Midorikawa S.-I., Binocular diplopia and ptosis due to snakebite (Agkistrodon blomhoffi "mamushi")-a case report. Brain and Nerve 2010 62 3 273 277 2-s2.0-77949829758
10. Enokida H., Gotanda T., Oku S., Imazono Y., Kubo H., Hanada T., Suzuki S., Inomata K., Kishiye T., Tahara Y., Nishiyama K., Nakagawa M., Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Japanese Journal of Cancer Research 2002 93 9 1037 1046 10.1111/j.1349-7006.2002.tb02481.x 2-s2.0-0036747416
11. Song Y.-C., Xia W., Jiang J.-H., Wang Q.-D., Reversal of multidrug resistance in drug-resistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism. Yaoxue Xuebao 2005 40 3 204 207 2-s2.0-18244390938
12. Kinoshita M., Eguchi Y., Hynynen K., Activation of Bak in ultrasound-induced, JNK- and p38-independent apoptosis and its inhibition by Bcl-2. Biochemical and Biophysical Research Communications 2007 353 2 515 521 10.1016/j.bbrc.2006.12.055 2-s2.0-33845806107
13. Zhou J., Liu M., Aneja R., Chandra R., Lage H., Joshi H. C., Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Research 2006 66 1 445 452 10.1158/0008-5472.CAN-05-1779 2-s2.0-31544463321
14. Huang C., Xu D., Ju J., Xia Q., Wang M., The regulatory mechanism of JNK signal transduction pathway-mediated multidrug-resistance in human hepatic cancer cell line Bel-7402/FU. Tumor 2014 34 1 10.3781/j.issn.1000-7431.2014.01.004
15. Miao Z.-H., Ding J., Transcription factor c-jun activation represses mdr-1 gene expression. Cancer Research 2003 63 15 4527 4532 2-s2.0-0042591363
16. Choi Y. K., Cho S.-G., Choi H. S., Woo S.-M., Yun Y. J., Shin Y. C., Ko S.-G., JNK1/2 activation by an extract from the roots of Morus alba L. reduces the viability of multidrug-resistant MCF-7/Dox cells by inhibiting YB-1-dependent Mdr1 expression. Evidence-Based Complementary and Alternative Medicine 2013 2013 10 741985 10.1155/2013/741985 2-s2.0-84881523091
17. Pan Q. W. Y., Qin J. C. L., Du B., Gold nanoparticles inhibit VEGF 165-induced migration and tube formation of endothelial cells via the akt pathway. BioMed Research International 2014 2014 11 418624 10.1155/2014/418624
18. Bray F., Møller B., Predicting the future burden of cancer. Nature Reviews Cancer 2006 6 1 63 74 10.1038/nrc1781 2-s2.0-30144445859
19. Goldman B., Multidrug resistance: can new drugs help chemotherapy score against cancer? Journal of the National Cancer Institute 2003 95 4 255 257 10.1093/jnci/95.4.255 2-s2.0-0037453894
20. Haginaka J., Kitabatake T., Hirose I., Matsunaga H., Moaddel R., Interaction of cepharanthine with immobilized heat shock protein 90 α (Hsp90 α) and screening of Hsp90 α inhibitors. Analytical Biochemistry 2013 434 1 202 206 10.1016/j.ab.2012.11.010
21. Shtil A. A., Azare J., Redundancy of biological regulation as the basis of emergence of multidrug resistance. International Review of Cytology 2005 246 1 29 10.1016/S0074-7696(05)46001-5 2-s2.0-25144494203
22. Zhang Y., Chen F., Reactive oxygen species (ROS), troublemakers between nuclear factor- B (NF- B) and c-Jun NH(2)-terminal kinase (JNK). Cancer Research 2004 64 6 1902 1905 10.1158/0008-5472.CAN-03-3361 2-s2.0-1542405935
23. Peng Y.-M., Wang N., Wang Y.-F., Han L., Zhang Y., Jiang J.-H., Zhou Y.-B., Wang Q.-D., Correlation between reversing effect of cepharanthine hydrochloride on multidrug resistance and P-glycoprotein expression and function of K562/ADR cells. Yaoxue Xuebao 2012 47 5 594 599 2-s2.0-84863651288
24. Seubwai W., Vaeteewoottacharn K., Hiyoshi M., Suzu S., Puapairoj A., Wongkham C., Okada S., Wongkham S., Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF- B. Cancer Science 2010 101 7 1590 1595 10.1111/j.1349-7006.2010.01572.x 2-s2.0-77954678536
25. Sullivan K., El-Hoss J., Little D. G., Schindeler A., JNK inhibitors increase osteogenesis in Nf1-deficient cells. Bone 2011 49 6 1311 1316 10.1016/j.bone.2011.09.043 2-s2.0-81355160356
26. Valesio E. G., Zhang H., Zhang C., Exposure to the JNK inhibitor SP600125 (anthrapyrazolone) during early zebrafish development results in morphological defects. Journal of Applied Toxicology 2013 33 1 32 40 10.1002/jat.1708 2-s2.0-84870390611
27. Dunn C., Wiltshire C., MacLaren A., Gillespie D. A. F., Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cellular Signalling 2002 14 7 585 593 10.1016/S0898-6568(01)00275-3 2-s2.0-0036223297
28. Albanito L., Reddy C. E., Musti A. M., C-Jun is essential for the induction of Il-1 β gene expression in in vitro activated Bergmann glial cells. Glia 2011 59 12 1879 1890 10.1002/glia.21244 2-s2.0-80053568025
29. Sui H., Zhou S., Wang Y., Liu X., Zhou L., Yin P., Fan Z., Li Q., COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011 32 5 667 675 10.1093/carcin/bgr016 2-s2.0-79955775908